BDTX BLACK DIAMOND THERAPEUTICS I revenue, earnings and financials

For the quarter ended June 30, 2026, BLACK DIAMOND THERAPEUTICS I reported revenue of $0, net income of −$9.91M and diluted EPS of −$0.17; over the last four quarters revenue was $0 and net income $22.3B; for the fiscal year ended December 2025 revenue was $70.0M.

BDTX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $70.0M, gross profit n/a, operating income $12.5M, net income $22.4B (margin 31952.9%), EPS $0.39
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$78.8M, net income −$69.7B (margin n/a), EPS −$1.27
• Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$86.5M, net income −$82.4M (margin n/a), EPS −$1.88
• Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$92.8M, net income −$91.2M (margin n/a), EPS −$2.52
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$127M, net income −$126M (margin n/a), EPS −$3.47

BDTX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0, net income −$9.91M, EPS −$0.17
• Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$9.04M, EPS −$0.16
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income $22.3B, EPS −$0.25
• Quarter ended Sep 30, 2025: revenue $0, net income −$8.50M, EPS −$0.15
• Quarter ended Jun 30, 2025: revenue $0, net income −$10.6M, EPS −$0.19
• Quarter ended Mar 31, 2025: revenue $70.0M, net income $56.5M, EPS $0.98
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$69.6B, EPS −$0.28
• Quarter ended Sep 30, 2024: revenue $0, net income −$15.6M, EPS −$0.28
• Quarter ended Jun 30, 2024: revenue $0, net income −$19.9M, EPS −$0.36
• Quarter ended Mar 31, 2024: revenue $0, net income −$18.2M, EPS −$0.35
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$19.4M, EPS −$0.34
• Quarter ended Sep 30, 2023: revenue n/a, net income −$23.0M, EPS −$0.45
• Quarter ended Jun 30, 2023: revenue n/a, net income −$19.2M, EPS −$0.52
• Quarter ended Mar 31, 2023: revenue n/a, net income −$20.9M, EPS −$0.57
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$21.1M, EPS −$0.59
• Quarter ended Sep 30, 2022: revenue n/a, net income −$21.7M, EPS −$0.60
• Quarter ended Jun 30, 2022: revenue n/a, net income −$22.9M, EPS −$0.63
• Quarter ended Mar 31, 2022: revenue n/a, net income −$25.5M, EPS −$0.70
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$25.9M, EPS −$0.71
• Quarter ended Sep 30, 2021: revenue n/a, net income −$35.1M, EPS −$0.97

BDTX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $29.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$62.3M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$66.7M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$85.1M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$100M, share buybacks n/a

BDTX balance sheet

• Jun 30, 2026: cash $19.2M, total assets $125M, total liabilities $28.9M, shareholders' equity $96.1M
• Mar 31, 2026: cash $30.1M, total assets $133M, total liabilities $28.6M, shareholders' equity $104M
• Dec 31, 2025: cash $21.0M, total assets $143M, total liabilities $30.8M, shareholders' equity $112M
• Sep 30, 2025: cash $30.9M, total assets $158M, total liabilities $31.6M, shareholders' equity $126M
• Jun 30, 2025: cash $30.0M, total assets $166M, total liabilities $33.8M, shareholders' equity $133M
• Mar 31, 2025: cash $98.4M, total assets $176M, total liabilities $34.7M, shareholders' equity $142M
• Dec 31, 2024: cash $36.4M, total assets $123M, total liabilities $39.4M, shareholders' equity $83.3M
• Sep 30, 2024: cash $23.4M, total assets $138M, total liabilities $40.5M, shareholders' equity $97.4M

What is BDTX's revenue?

BLACK DIAMOND THERAPEUTICS I reported $0 of revenue over its last four quarters, through June 30, 2026.

Is BDTX profitable?

Yes. BLACK DIAMOND THERAPEUTICS I earned $22.3B over the last four quarters.

What is BDTX's EPS?

Diluted earnings per share over the last four quarters were −$0.73; −$0.17 in the latest quarter.

BDTX ownership and insider trades · All stocks